MedPath

Empagliflozin

Generic Name
Empagliflozin
Brand Names
Glyxambi, Jardiance, Synjardy, Trijardy
Drug Type
Small Molecule
Chemical Formula
C23H27ClO7
CAS Number
864070-44-0
Unique Ingredient Identifier
HDC1R2M35U
Background

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.

The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. remogliflozin etabonate), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of canagliflozin in 2013 and both dapagliflozin and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or as a combination product with metformin.

An extended-release combination product containing empagliflozin, metformin, and linagliptin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.

Empagliflozin is also approved to reduce the risk of cardiovascular mortality and hospitalization due to heart failure in adult patients with heart failure, either alone or in combination with metformin. It is also indicated in adults to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.

Empagliflozin is not approved for use in patients with type 1 diabetes.

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
Monotherapy
Clinical Trials
Related News

NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry

• India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin. • The price regulations follow the March 11, 2025 expiry of Boehringer Ingelheim's empagliflozin patent, opening the market to multiple pharmaceutical companies including Mankind Pharma, Lupin, and Alkem Laboratories. • Beyond diabetes medications, the NPPA's pricing decisions also cover anti-hypertensive combinations containing telmisartan and metoprolol, as well as anti-inflammatory formulations with paracetamol and mefenamic acid.

Trump's Executive Order Delays Medicare Drug Price Negotiations, Sparking Industry and Policy Debate

• President Trump signed an executive order extending the exemption period for small-molecule drugs from Medicare price negotiations by four years, a move criticized by advocacy groups as favoring pharmaceutical industry interests. • The order aims to address what the administration calls the "pill penalty" - the current policy where small-molecule drugs (90% of medications) face negotiations after 9 years while biologics have longer exemption periods. • The Medicare Drug Price Negotiation Program, established under the Biden administration, had already achieved price reductions of 38-79% on 10 high-cost drugs with projected savings of $6 billion if applied in 2023.

SGLT2 Inhibitors Demonstrate Significant Renal Benefits in Heart Failure and Chronic Kidney Disease

• SGLT2 inhibitors significantly reduce the risk of acute kidney injury and renal failure in heart failure patients, with empagliflozin showing a 30% reduction in kidney injury risk according to a meta-analysis of over 10,000 participants. • A new study reveals SGLT2 inhibitors effectively increase hemoglobin and hematocrit levels in chronic kidney disease patients, potentially addressing anemia—a common complication—while providing established renoprotective benefits. • Despite strong clinical evidence supporting their cardiorenal benefits, SGLT2 inhibitors remain underprescribed, prompting the development of collaborative prescription algorithms and educational initiatives to improve utilization in primary care settings.

2025 Pharmaceutical Pipeline: Major Patent Expirations Set to Transform Drug Market with Generics and Biosimilars

• The US pharmaceutical market is poised for significant change in 2025 as several blockbuster drugs including Xarelto, Entresto, and Stelara face patent expirations, opening the door to generic and biosimilar competition. • Multiple biosimilars for ustekinumab (Stelara) are entering the market in 2025, with Wezlana already launched in January as the first interchangeable biosimilar, while other major drugs like ticagrelor and denosumab will also face competition. • The pharmaceutical pipeline continues to expand with innovative therapies for cancer and neurological disorders, alongside the Medicare Drug Price Negotiation program which will further impact pricing dynamics for high-cost medications.

Novo Nordisk Warns US Price Negotiations Will Impede Research as Three GLP-1 Drugs Face Scrutiny

• Novo Nordisk has expressed strong concerns that three of its best-selling GLP-1 drugs have been included in upcoming US price negotiations, warning this will slow down research and development efforts. • The Danish pharmaceutical giant faces increasing pressure from US payers amid a shifting market landscape, forcing the company to adapt its strategy toward next-generation innovation and expansion in emerging markets. • While navigating pricing challenges, Novo Nordisk continues to advance its pipeline, including semaglutide formulations and digital insulin delivery systems, to maintain its leadership position in diabetes and obesity treatment.

Boehringer Ingelheim Prepares for Multiple New Product Launches in 2025 Following Strong R&D Investment

• Boehringer Ingelheim reached 66 million patients in 2024, an 8% increase from the previous year, while investing €6.2 billion (23.2% of net sales) in research and development. • The company is preparing to launch zongertinib, potentially the first oral targeted therapy for HER2-mutated lung cancer, and nerandomilast for pulmonary fibrosis, with both anticipated for US release in late 2025. • Human Pharma sales rose 7% to €21.9 billion, led by JARDIANCE® and OFEV®, with over ten new Phase II and III trials planned in the next 12-18 months.

Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost

• Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility. • Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet. • The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.

GLP-1 Agonists Linked to Reduced Risk of 42 Health Conditions in Large Study

• A large observational study of nearly 2 million patients found that GLP-1 receptor agonists (GLP-1RAs) are associated with a reduced risk of 42 health conditions. • The study, which included 215,000 GLP-1RA users, showed benefits beyond glucose control and weight loss, including neurological and respiratory conditions. • While GLP-1RAs demonstrated broad benefits, the study also identified increased risks for certain conditions like kidney stones and low blood pressure. • Researchers emphasize the need for further studies to confirm these findings and understand the long-term effects of GLP-1RA therapy.

Cytokinetics Halts ALS Drug Trial and Faces FDA Rejection for Heart Failure Treatment

• Cytokinetics stopped the Phase 3 COURAGE-ALS trial of resedemtiv for amyotrophic lateral sclerosis (ALS) after a futility analysis showed no benefit over placebo. • The FDA rejected Cytokinetics' omecamtiv mecarbil for heart failure, citing insufficient efficacy data, increasing the likelihood that the company will shelve the drug. • Cytokinetics is now focusing on aficamten, a cardiac myosin inhibitor in Phase 3 development for hypertrophic cardiomyopathy (HCM), with results expected later in 2023.

FDA Approves Bayer/Merck & Co Heart Failure Drug Verquvo

The FDA has approved Bayer and Merck & Co's heart failure drug, Verquvo (vericiguat), for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45%. This approval introduces a new option in a competitive market, following the results of the pivotal phase 3 VICTORIA trial.

FDA Approves New Heart Failure Use for AZ's Farxiga

The FDA has approved AstraZeneca's Farxiga for a new use, reducing the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with or without type 2 diabetes. This approval is based on positive results from the phase 3 DAPA-HF trial.

Finerenone sNDA Submitted to FDA for Heart Failure with Preserved Ejection Fraction

• Bayer has submitted a supplemental New Drug Application (sNDA) to the FDA for finerenone to treat heart failure patients with LVEF ≥40%. • The sNDA is based on the Phase III FINEARTS-HF trial, which demonstrated a 16% reduction in cardiovascular death and heart failure events. • Finerenone is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) already approved for chronic kidney disease in type 2 diabetes. • If approved, finerenone could address a significant unmet need in heart failure patients with mildly reduced or preserved ejection fraction.

GLP-1 and SGLT2 Drugs Reduce Risk of Stroke Recurrence and Death in Survivors

• GLP-1 receptor agonists like Ozempic and SGLT2 inhibitors such as Jardiance significantly reduce the risk of death and heart attack in stroke survivors. • A study found that stroke patients taking either GLP-1 or SGLT2 drugs had a 74% lower risk of death and an 84% lower risk of heart attack. • SGLT2 inhibitors were also associated with a 67% reduced risk of recurrent stroke, highlighting their potential for secondary prevention. • Experts emphasize the need for clinical trials to confirm these findings and integrate these medications into standard stroke aftercare.

Boehringer Ingelheim Plans 25 New Treatments by 2030, Bolstered by Oncology and Metabolic Disease Programs

• Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, cardiovascular, renal, and metabolic diseases. • Key candidates include Brigimadlin, an MDM2-p53 agonist for dedifferentiated liposarcoma, and zongertinib, a HER2 tyrosine kinase inhibitor, showing promising early data. • Survodutide, a glucagon/GLP-1 candidate, demonstrated significant improvement in liver disease due to metabolic dysfunction-associated steatohepatitis in Phase II trials. • Despite slow sales of its Humira biosimilar, Cyltezo, Boehringer reported a 9.7% net sales increase in 2023, driven by Jardiance and Ofev.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy